What is known? – The incidence of transthyretin amyloid cardiomyopathy (ATTR-CA) is increasing due to improvements in diagnostic pathways and it has recently overtaken light chain amyloidosis as the commonest manifestation of amyloid worldwide. Can lessons be learnt about the feasibility of delivering multicentre specialist amyloidosis care using a hub-and-spoke model? Not all UK patients with cardiac amyloidosis are willing to travel long distances to access expert care, but it is feasible to deliver highly specialised healthcare via a network supported by a central hub. This study highlights a growing need to implement a UK amyloidosis network to avoid inequalities in the access to, and quality of, specialised healthcare.
【저자키워드】 Screening, amyloidosis, Transthyretin amyloid cardiomyopathy,